drugset / Trial / NCT00176891

Stem Cell Transplant w/Laronidase for Hurler

NCT00176891

Phase 2 Completed 25 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.

Timeline

Start
2004-03
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject laronidase Protein / enzyme biologic Intravenous

Indications